Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results
08 août 2018 07h00 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business...
Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors
23 juil. 2018 07h30 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has...
Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
13 juin 2018 07h00 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
Leap Therapeutics Reports First Quarter 2018 Financial Results
11 mai 2018 07h00 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
16 avr. 2018 09h00 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the...
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
27 mars 2018 16h05 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
23 mars 2018 09h00 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Leap Therapeutics Announces Proposed Public Offering of Common Stock
22 mars 2018 16h05 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference
21 mars 2018 07h00 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 21, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
14 mars 2018 17h00 HE
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising...